athogenic SMAD3 mutations are a known cause of early aortic dilatation and dissection. In combination with osteoarthritis at young age this is encapsulated in the aneurysms-osteoarthritis syndrome.
The mean rate of increase in aorta diameter in the normal population is 0.07 and 0.09 mm per year of life in women and men, respectively. 3 The natural course of this process is influenced by many factors such as age, sex, and blood pressure. In the past decade, much attention has been paid to genetic aortopathies. In Marfan syndrome, for example, the aorta dilates fastest at the level of the sinus of Valsalva with a rate of ≈0.49±0.5 mm per year. 4 In comparison to Loeys-Dietz syndrome, where the aorta can grow at rates of up to 10 mm/y, dilatation in our cohort may seem relatively mild. 5 However, in earlier studies mortality was high, and although no deaths occurred during our follow-up, it should be noted that this could be explained by the intensive management and preventive surgery at relatively mild dilatation of the aorta.
The current results differ from a previous report from our group, especially in growth rate and location of fastest growth, which can be explained by longer follow-up duration, inclusion of milder cases discovered by family screening, and by using different analysis methods. Still, we can appreciate that SMAD3 mutation carriers show aortic dilatation at a rate similar to other genetic aortopathies, dilatation occurs predominantly at the sino-tubular junction and ascending aorta, but also in all other parts of the aorta and large arteries. With this study we provide evidence that SMAD3 mutations cause an aggressive form of aortic dilatation, warranting vigilant follow-up. The fastest growth rate (0.4 mm/y) was observed at the level of the sino-tubular junction. In 64% (18 of 28) of the patients in this study, a potentially fatal arterial pathology was discovered. However, for the management of SMAD3 patients this implies that the current protocol adequately addresses the clinical problem in these patients as no patients died from aortic rupture or suffered from aortic dissection during follow-up. Additionally, this study provides an important measure of reference to other known causes of genetic aortopathies. More research is needed to determine predictors for fast growth and possible medical therapies in SMAD3 patients hopefully resulting in a better understanding and improved outcome.
